Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
2 reports, 2 independent
Updated Jun 30
Gone quiet
- Reports
- 2
- Developments
- 5
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The Administration negotiated confidential deals on drug prices using HHS officials, involving major pharmaceutical companies.Sub-event
- Medicare reimbursement rules affect market stability for Nuo Therapeutics, Inc.Sub-event
- Medicare negotiates volume discounts on drugs, while lobbying efforts block government cost-trimming.Sub-event
Digital Realty Trust bought into data centers from Blackstone, while Reuters reported on a U.S. House committee probe into drugmakers, involving AbbVie and Merck.1 source
Big pharma companies are negotiating pricing exemptions due to Medicare system changes.1 source
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
Eli Lilly and Company
American pharmaceutical company
-
Merck
public company in Indonesia
Related events
- Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.